Blastic plasmacytoid dendritic neoplasm (BPDCN) is a rare but aggressive hematologic malignancy that often manifests with asymptomatic skin lesions that often appear as bruise-like lesions, plaques or nodules. With one approved drug available, researchers are studying additional investigational agents.
While little is known about BPDCN and how to treat it, authors of a recent study suggest a low threshold for performing a skin biopsy to evaluate skin lesions in patients with hematological cancers, especially when those lesions that are quickly progressing, large or involve atypical sites.
Researchers make headway in determining life-prolonging treatment for blastic plasmacytoid dendritic cell neoplasm, a rare cancer that is often associated with skin manifestations.
Blastic plasmacytoid dendritic cell neoplasm isn’t a skin cancer. Yet, dermatologists might be the first providers to encounter these patients.